Clinical Trial Update: Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Docetaxel to Abiraterone as first-line therapy in metastatic castration-resistant prostate cancer with intraductal prostate carcinoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: West China Hospital | Conditions: Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: UNKNOWN